Journal
JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE
Volume 6, Issue 4, Pages 253-260Publisher
WILEY
DOI: 10.1002/term.427
Keywords
gelatin; bone morphogenetic protein-2 (BMP-2); controlled drug release; mesenchymal stem cell; osteogenesis
Categories
Funding
- Ministry of Education, Culture, Sports, Science and Technology, Japan
Ask authors/readers for more resources
Bone marrow mesenchymal stem cells (MSCs) have been used for bone tissue engineering due to their osteogenic differentiation capability, but their application is controversial. To enhance their capability, we prepared biodegradable gelatin sponges incorporating beta-tricalcium phosphate ceramics (GT sponge), which has been shown to possess excellent controlled drug-release properties. The GT sponge was used as a carrier for both rat MSCs and bone morphogenetic protein-2 (BMP-2) and osteogenic differentiation was assessed by subcutaneous implantation of four different kinds of implants, i.e. GT-alone, MSCGT composites, BMPGT composites and BMPGT composites supplemented with MSCs (BMPMSCGT) in rats. Two weeks after implantation, histological sections showed new bone formation in the peripheral parts of the BMPGT and in almost the total volume of the BMPMSCGT implants. After 4 weeks, histology as well as microCT analyses demonstrated extensive bone formation in BMPMSCGT implants. Gene expression and biochemical analyses of both alkaline phosphatase and bone-specific osteocalcin confirmed the histological findings. These results indicate that the combination of MSCs, GT and BMP synergistically enhances osteogenic capability and provides a rational basis for their clinical application in bone reconstruction. Copyright (c) 2011 John Wiley & Sons, Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available